The anti-dyskinetic and the anti-parkinsonian effects of sub-anesthetic ketamine are also present in female preclinical models

Sub-anesthetic ketamine (20 mg/kg, i.p.) significantly attenuates progressive L-DOPA-induced dyskinesia development in female unilateral 6-OHDA-lesioned Sprague-Dawley rats.

• Why it matters: Females are underrepresented in Parkinson’s disease and L-DOPA-induced dyskinesia preclinical work, leaving uncertainty about whether ketamine’s therapeutic effects generalize beyond males.
• What they did: Female unilateral 6-OHDA-lesioned rats received repeated L-DOPA with ketamine using a 10-h dosing paradigm, and dyskinesia progression was assessed in an attenuation model.
• The result: Early ketamine intervention modified the trajectory of LID expression, supporting sustained anti-dyskinetic potential in female preclinical models.

AI summary of the abstract · may contain errors · not medical advice · read the paper.